Suggested remit - To appraise the clinical and cost effectiveness of atezolizumab within its marketing authorisation for untreated non-squamous non-small-cell lung cancer
Topic has been suspended
 
Status Suspended
Process STA 2018
ID number 1495

Project Team

Project lead Emily Richards

Email enquiries

Timeline

Key events during the development of the guidance:

Date Update
22 January 2020 Suspended, Topic has been suspended
22 January 2020 The Department for Health and Social Care has asked NICE to carry out a Single Technology Appraisal of atezolizumab with carboplatin or cisplatin and pemetrexed for untreated advanced non-squamous non-small-cell lung cancer. For information, the company have advised that they are no longer pursuing a Marketing Authorisation Application from the European Medicines Agency for this indication at this time. Therefore, NICE has decided to suspend this appraisal from its current work programme. As this appraisal has been referred NICE will continue to monitor any development and will update interested parties if the situation changes.
18 July 2019 - 15 August 2019 Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators
07 June 2019 As you will be aware, the Department for Health and Social Care has asked NICE to carry out a Single Technology Appraisal of atezolizumab with carboplatin or cisplatin and pemetrexed for untreated advanced non-squamous non-small-cell lung cancer. Following on from information received from the company, please note that the timelines for this appraisal have been revised and the appraisal is now anticipated to begin in mid- November 2019.
11 January 2019 As you will be aware, the Department for Health and Social Care has asked NICE to carry out a Single Technology Appraisal of atezolizumab with carboplatin or cisplatin and pemetrexed for untreated advanced non-squamous non-small-cell lung cancer. Following on from information received from the company, please note that the timelines for this appraisal have been revised and the appraisal is now anticipated to begin in late September 2019.
02 October 2018 - 30 October 2018 Consultation on suggested remit, draft scope and provisional matrix of consultees and commentators
22 October 2018 On receiving updated regulatory timing information from the company that markets the technology, NICE has agreed that scoping the topic at this time would not be appropriate. Consequently the consultation on the draft scope will not continue. The consultation will be rescheduled to take place in line with anticipated regulatory approval timings. We apologise for any inconvenience this may cause. If you have any comments or concerns please contact the project manager for this proposed appraisal Emily Richards on (44 (0)161 413 4070 or via email on emily.richards@nice.org.uk
24 April 2018 In progress, Topic referred

For further information on how we develop guidance, please see our page about NICE technology appraisal guidance